50 years of sincere pharmaceutical industry to create a new legend of marine medicine

[China Pharmaceutical network enterprise news] Yan Yiyi, chairman of sincere pharmaceutical, said that drugs are related to people's health and safety, and product production quality is the first Profit should focus on quality, loss should focus on quality, quality is efficiency One of his secrets is to pay close attention to quality "To run a high-tech pharmaceutical enterprise well, the key is to focus, to look forward, and to be more down-to-earth," he said For a long time, environmental protection has been regarded as the key project of sincere pharmaceutical industry by Yan Yiyi (picture source: Baidu picture) on March 15, 2017, sincerity pharmaceutical was listed on the Shanghai Stock Exchange Become the 20th listed company in Wenzhou As a "pharmaceutical enterprise" founded in 1966, after more than half a century of trials and hardships, sincerity pharmaceutical industry has become a comprehensive modern pharmaceutical enterprise specializing in the production of capsules, injections, tablets, APIs and pharmaceutical intermediates Yan Yiyi, chairman of sincere pharmaceutical, said that since its establishment in 1966, sincere pharmaceutical has been 50 years in business, 50 years in wind and rain, and 50 years in harvest From a small factory of "two big tanks" for the family members of the army, taking root on the island, sticking to its main business, to a well-known enterprise in the national pharmaceutical industry, it has gone through a struggle paved with hard work and sweat After the IPO, the sincerity pharmaceutical industry will be able to realize the comprehensive upgrade of the company's preparation building, R & D center and marketing network, and the company's ability in R & D, production and sales will be further improved as a whole, which will continue to promote the sustainable and stable development of the sincerity pharmaceutical industry in the future In October 1966, Tongshan pharmaceutical factory, the predecessor of sincerity pharmaceutical industry, was established in Dongtou County, Wenzhou City, Zhejiang Province In the next half century, sincerity pharmaceutical industry has made a series of outstanding achievements and honorary awards In 1986, the company won the second prize of Wenzhou science and Technology Progress Award; in 1992, the company was rated as a technology progress enterprise; in 1995, the company was rated as a AAA credit enterprise in Zhejiang Province; in 2001, the company became the first pharmaceutical enterprise in Wenzhou City to fully pass the GMP certification; in 2009, the company was recognized as a provincial enterprise technology center; In 2013, sincerity pharmaceutical became one of the top 500 pharmaceutical enterprises in Wenzhou As an old brand pharmaceutical enterprise, sincerity pharmaceutical industry has also made great achievements in product quality In 1996, amikacin sulfate injection produced by the company was rated as "high quality pharmaceutical product" in 1995 in Zhejiang Province; in 1999, the company passed GMP certification of TGA in Australia; in 2000, ribavirin and acyclovir produced by sincerity pharmaceutical industry were rated as "high quality pharmaceutical product" in 1999 in Zhejiang Province; in 2005, the company passed the certification of the United Kingdom and the United States Since then, in 2010, the three APIs of sincerity pharmaceutical industry have passed the joint certification of FDA, EMEA, TGA and SDA, which is also a global scale joint certification The product quality has been unanimously recognized by both China and foreign countries In fact, this series of achievements is the sincere pharmaceutical industry In the spirit of "diligence, preciseness, innovation and dedication" for more than 50 years, it insists on no falsification in production and operation, no falsification in enterprise performance, no falsification in product quality, no falsification in environmental protection management, no falsification in products, excellent services and good reputation, just like the name "sincerity", it sincerely serves customers , recognition of safe and effective health protection On the other hand, on March 15 this year, sincerity pharmaceutical successfully listed on the main board of the Shanghai Stock Exchange, which also shows the affirmation of its development status and future potential from supervision and intermediary agencies Yan Yiyi, the sincere "leader", can not be ignored Today's sincere pharmaceutical industry is also inseparable from Yan Yiyi, the actual controller and chairman of the company Born in 1949, Yan Yiyi is a manager He has successively served as the factory director of Tongshan pharmaceutical factory in Dongtou County, the factory director of Wenzhou No.3 pharmaceutical factory, the chairman and general manager of Zhejiang sincerity Pharmaceutical Co., Ltd., and the executive director and general manager of import and export of Wenzhou San Pharmaceutical Co., Ltd.; now he is the executive director of Jiangsu sincerity, the chairman of sincerity small loan company and the chairman of Zhejiang sincerity Pharmaceutical Co., Ltd Over the years, he has won the titles of Municipal Communist Party member, municipal labor model, Chinese entrepreneur, provincial and municipal entrepreneur, and municipal meritorious entrepreneur It is understood that Yan Yiyi has been a "sincere person" with 48 years of factory experience In the late 1970s, due to the single product and other reasons, the predecessor of sincere pharmaceutical industry was insolvent, and the enterprise was on the verge of bankruptcy In 1980, Yan Yiyi made a profit of 1000 yuan, reversing the loss situation for three consecutive years Yan Yiyi said that drugs are related to people's health and safety, and product production quality is the first Profit should focus on quality, loss should focus on quality, quality is efficiency One of his secrets is to pay close attention to quality Yan Yiyi said that the future belongs to an ecological enterprise Yan Yiyi put forward the principle of "three no harm" to the enterprise's environmental protection, that is, no harm to itself, no harm to the surrounding areas, no harm to future generations For this reason, sincerity pharmaceutical invested 30 million yuan to build the "three wastes treatment center" of environmental protection public works in 2005, and fully implemented the construction of waterless workshop, comprehensively carried out the repair of the old and the recycling of the waste, and changed the waste into treasure, so as to make environmental protection awareness and sustainable production deeply rooted in the hearts of the enterprise; In addition, the production of APIs has been greatly innovated, starting to change the small and more reactive mode into the large and less intensive production mode During the 12th Five Year Plan period, sincerity pharmaceutical increased the production and sales of pharmaceutical products, reducing the proportion of API output value from 85% to 50% Yan Yiyi has a clear strategic plan for sincerity pharmaceutical industry "To run a high-tech pharmaceutical enterprise well, the key is to focus, to look forward, and to be more down-to-earth," he said For a long time, environmental protection has been regarded as the key project of sincere pharmaceutical industry by Yan Yiyi "Small but beautiful" layout has broad prospects In the first quarter of this year, the revenue and net profit of sincere pharmaceutical industry continued to rise In the first quarter, the revenue reached 82.31 million yuan, up 16.48% year-on-year, and the net profit was 14.18 million yuan, up 23.75% year-on-year The company's main business revenue mainly came from six categories of products, including joint drugs, antiviral drugs, anti-tumor drugs, tranquilizing and brain tonifying drugs, diuretic drugs and intermediates 。 Located on the island, sincerity pharmaceutical is committed to the development of small varieties of "marine green drugs" and "big disease drugs" At present, the main products include glucosamine hydrochloride APIs and preparations, torasemide injection and capsules, gastrodin APIs, ribavirin and azathioprine APIs, etc In the main products, sincerity pharmaceutical industry can be called the best in China Taking glucosamine hydrochloride as an example, at present, the top four domestic manufacturers of this product are sincerity pharmaceutical, Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., Aomei pharmaceutical and Shanxi zhongyuanwei Pharmaceutical Co., Ltd According to the statistics of CFDA Nanfang Institute, in 2015, the market share of the first four manufacturers totaled 79.66%, and the market share of glucosamine hydrochloride preparations of sincerity pharmaceutical industry increased from 9.97% in 2011 to 26.11% in 2015, ranking first At present, the top three manufacturers of torasemide are Nanjing Youke Pharmaceutical Co., Ltd., Haichen Pharmaceutical Co., Ltd and sincerity Pharmaceutical Co., Ltd According to the statistics of CFDA Nanfang Institute, the market share of the first three manufacturers in 2015 totaled 84.94%, of which the market share of sincerity pharmaceutical industry was 12.39%, ranking the third At present, there are only three manufacturers producing and selling synthetic gastrodin APIs in China, namely sincerity pharmaceutical, Chongqing Southwest Pharmaceutical No.2 factory and Jiangsu HanStone pharmaceutical In recent three years, the sales volume of sincerity pharmaceutical industry has maintained, accounting for about half of the market, of which the sales market share in 2015 was 48.93% In the market of ribavirin API, the competition pattern is basically stable, and a market pattern has been formed with Guangdong Zhaoqing Xinghu Biotechnology Co., Ltd as the leader, Xinxiang pharmaceutical Co., Ltd and sincerity Pharmaceutical Co., Ltd as the followers, which account for nearly 90% of the market According to the statistics of CFDA South Institute, in 2015, the market share of ribavirin API was about 5.57%, ranking the third In the market of azathioprine, the sales volume of azathioprine API of sincerity pharmaceutical industry exceeds 80% of the total azathioprine API market, almost in the state of no competitors, playing a leading role in the market Due to the advanced technology adopted in the production of sincerity pharmaceutical industry, the limit of impurities is lower than the legal standard, and it has maintained long-term cooperation with many large pharmaceutical companies in Europe and America It is a large exporter of azathioprine APIs in China, accounting for more than 80% of the export volume In addition, it is worth mentioning that the products mainly produced by sincere pharmaceutical industry also have considerable market growth space Among them, in recent years, the sales volume of glucosamine hydrochloride in China has increased by more than 20% every year From 431 million yuan in 2009 to 2.309 billion yuan in 2015, with an average annual growth rate of 32.28%, which is significantly higher than the growth rate of the overall drug market of osteoarthritis According to the prediction of CFDA South Institute, the market scale of domestic glucosamine hydrochloride preparation may exceed 4.1 billion yuan by 2018 As a new generation of loop diuretics, according to the data of CFDA Nanfang Institute, torasemide's share in the diuretic market increased from 66.13% in 2010 to 76.45% in 2015, with a significant upward trend Its advantages with other varieties continue to expand, becoming the leading type of diuretic drugs From 2008 to 2015, the sales increased from 324 million yuan to 1118 million yuan, with a compound growth rate of 19.35% According to the prediction of CFDA Nanfang Institute, the overall market size of torasemide will exceed 1.7 billion yuan by 2018 In addition, the sales volume of gastrodin API in China increased from 33.018 million yuan in 2010 to 81.1067 million yuan in 2015, with a compound growth rate of 19.69% In the future, the market output and sales volume will maintain stable growth The azathioprine API market achieved a compound growth rate of 24.92% from 2010 to 2015 According to the forecast of CFDA Nanfang Institute, the sales volume of azathioprine API market will show an increasing trend in the next two years It is estimated that by 2017, the market volume of azathioprine APIs in China will reach 34.93 tons, mainly for export Looking into the future, Yan Yiyi said that sincere pharmaceutical industry will continue to adhere to innovation as the driving force, talent as the basis, market-oriented, strengthen scientific research, accelerate product upgrading and upgrading, promote product structure transformation from API to preparation, and improve core competitiveness; it will further standardize the company's operation, seize the opportunity, expand and forge ahead, take a broad view, accumulate and develop Sincerity pharmaceutical will take marine medicine, biopharmaceutical, traditional Chinese medicine and new preparations as its main development direction, develop health industry, implement marketing reform, and strive to build the company's core competitiveness; By virtue of the advantages of landing on the main board of Shanghai Stock Exchange, and by means of acquisition, merger, share holding and other forms, the company will enter the capital market in a planned, step-by-step and actively and steadily, so as to extend the industrial chain, realize the leapfrog development of the company, and create a new legend of marine medicine.